Clinical trial · Interventional
Autologous Killer Cell Therapy in Colon Cancer Patients
Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 patients with confirmed stage IV colon carcinoma with metastasis will be assigned into two groups. Patients in both groups will receive the same therapeutic regimen as usual. Patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer Stage IV | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy AND/OR Radiation Therapy | Other | — | UNRESOLVED |
| Cytokine-induced killer cell | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CIK Intervention plus routine treatment
- description
- Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
- interventionNames
- Biological: Cytokine-induced killer cell
- Other: Chemotherapy AND/OR Radiation Therapy
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Patients who receive routine treatments only (chemotherapy, radiation therapy)
- interventionNames
- Other: Chemotherapy AND/OR Radiation Therapy
Primary outcomes (3)
- measure
- Safety of administering CIK cells plus chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed colorectal cancer at stage IV * ECOG performance status 0-2 * Adequate cardiac/renal/hepatic function * Adequate bone marrow function (blood cell count) Exclusion Criteria: * Patients that have received prior chemotherapy or immune cell therapy * Patients that have previously participated in another clinical trial * History of positive test result for HIV, HBV, HCV, HTLV-1, syphilis * Presence of Active infections * Patients with immunodeficiencies, autoimmunities, or severe allergies * Receiving immunosuppressive regimens
References
Publications (0)
Data not yet available